![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety and Efficacy of DTG by Age, Race and Gender: Subgroup Analysis of 96 Week Results From Treatment-Naive Patients in Phase III Trials (SPRING-2 [ING113086], SINGLE [ING114467] and FLAMINGO [ING114915])
|
|
|
Reported by Jules Levin
8th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2015; Vancouver, Canada
Koteff,1 R Cuffe,2 C Granier,3 A Zolopa,1 A Murungi,2 B Wynne,4 M Aboud,2 K Smith1 1ViiV Healthcare, Research Triangle Park, NC, USA; 2ViiV Healthcare, Middlesex, United Kingdom; 3GlaxoSmithKline, London, United Kingdom; 4GlaxoSmithKline, Research Triangle Park, NC, USA
![IAS1.gif](../images/072415/072415-7/IAS1.gif)
![IAS2.gif](../images/072415/072415-7/IAS2.gif)
![IAS3.gif](../images/072415/072415-7/IAS3.gif)
![IAS5.gif](../images/072415/072415-7/IAS5.gif)
![IAS6.gif](../images/072415/072415-7/IAS6.gif)
![IAS7.gif](../images/072415/072415-7/IAS7.gif)
![IAS8.gif](../images/072415/072415-7/IAS8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|